1. Home
  2. FSK vs CPRX Comparison

FSK vs CPRX Comparison

Compare FSK & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FSK

FS KKR Capital Corp.

HOLD

Current Price

$10.35

Market Cap

3.0B

Sector

Finance

ML Signal

HOLD

Logo Catalyst Pharmaceuticals Inc.

CPRX

Catalyst Pharmaceuticals Inc.

HOLD

Current Price

$31.42

Market Cap

3.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FSK
CPRX
Founded
2007
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
3.4B
IPO Year
2008
2006

Fundamental Metrics

Financial Performance
Metric
FSK
CPRX
Price
$10.35
$31.42
Analyst Decision
Hold
Strong Buy
Analyst Count
8
1
Target Price
$13.19
$35.00
AVG Volume (30 Days)
2.9M
1.6M
Earning Date
05-11-2026
05-11-2026
Dividend Yield
18.82%
N/A
EPS Growth
N/A
28.24
EPS
N/A
0.50
Revenue
N/A
$119,072,803.00
Revenue This Year
N/A
$9.20
Revenue Next Year
N/A
$10.51
P/E Ratio
N/A
$62.84
Revenue Growth
N/A
16.39
52 Week Low
$9.72
$19.05
52 Week High
$22.68
$32.56

Technical Indicators

Market Signals
Indicator
FSK
CPRX
Relative Strength Index (RSI) 44.17 72.18
Support Level $9.85 $31.25
Resistance Level $10.56 $32.56
Average True Range (ATR) 0.27 0.04
MACD -0.06 -0.10
Stochastic Oscillator 30.61 81.31

Price Performance

Historical Comparison
FSK
CPRX

About FSK FS KKR Capital Corp.

FS KKR Capital Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation. The company's portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies.

About CPRX Catalyst Pharmaceuticals Inc.

Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.

Share on Social Networks: